glp 1 drugs and ulcerative colitis Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, therapeutic potential Weight Loss Medications & IBD

These areas can include your belly, the backs of your arms, your outer thighs and your upper buttocks

Neurogastroenterol Motil 2017;29

Kivimki, M

Patients should seek medical advice for persistent vomiting, severe abdominal pain, signs of hypoglycaemia, or symptoms of pancreatitis

This may include pacing your meals, avoiding rich foods during the first few weeks, increasing hydration, or modifying dosing schedules based on how your body responds

4 Challenges and future directions 4.1 Safety considerations The safety profile of dual or triple receptor agonists targeting GLP-1, GIP, and GCG receptors in the treatment of MASLD and related metabolic disorders warrants careful evaluation